Recurrent Head and Neck Cancer Clinical Trials

5 recruiting

Recurrent Head and Neck Cancer Trials at a Glance

6 actively recruiting trials for recurrent head and neck cancer are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Boston, Adelaide, and Albuquerque. Lead sponsors running recurrent head and neck cancer studies include BioNTech SE, Glenn J. Hanna, and Gruppo Oncologico del Nord-Ovest.

Browse recurrent head and neck cancer trials by phase

Treatments under study

About Recurrent Head and Neck Cancer Clinical Trials

Looking for clinical trials for Recurrent Head and Neck Cancer? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Head and Neck Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Head and Neck Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2Phase 3

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled193 locationsNCT04534205
Recruiting
Phase 1

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Head and Neck CancerMetastatic Head and Neck CancerRecurrent Head and Neck Cancer+1 more
Thomas Jefferson University6 enrolled1 locationNCT07501650
Recruiting
Phase 2

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Cancer+1 more
Glenn J. Hanna25 enrolled2 locationsNCT06239220
Recruiting
Not Applicable

Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study

Recurrent Head and Neck CancerLocal Cryotherapy Treatment
University Hospital, Strasbourg, France15 enrolled1 locationNCT05738187
Recruiting
Phase 2

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Head and Neck Squamous Cell Carcinoma (HNSCC)Metastatic Head and Neck CancerRecurrent Head and Neck Cancer
Gruppo Oncologico del Nord-Ovest67 enrolled8 locationsNCT06869473
Recruiting
Not Applicable

Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours

Locally Recurrent Head and Neck Cancer
University of Erlangen-Nürnberg Medical School96 enrolled1 locationNCT03238378